These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 30747306)

  • 1. Personalized Medicine and the Treatment of Hypertension.
    Melville S; Byrd JB
    Curr Hypertens Rep; 2019 Feb; 21(2):13. PubMed ID: 30747306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural selection and local adaptation of blood pressure regulation and their perspectives on precision medicine in hypertension.
    Hoh BP; Abdul Rahman T; Yusoff K
    Hereditas; 2019; 156():1. PubMed ID: 30636949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypertension pharmacogenomics: in search of personalized treatment approaches.
    Cooper-DeHoff RM; Johnson JA
    Nat Rev Nephrol; 2016 Feb; 12(2):110-22. PubMed ID: 26592190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalized medicine-a modern approach for the diagnosis and management of hypertension.
    Savoia C; Volpe M; Grassi G; Borghi C; Agabiti Rosei E; Touyz RM
    Clin Sci (Lond); 2017 Nov; 131(22):2671-2685. PubMed ID: 29109301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiological Phenotyping for Personalized Therapy of Uncontrolled Hypertension in Africa.
    Akintunde A; Nondi J; Gogo K; Jones ESW; Rayner BL; Hackam DG; Spence JD
    Am J Hypertens; 2017 Sep; 30(9):923-930. PubMed ID: 28472315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Riboflavin, MTHFR genotype and blood pressure: A personalized approach to prevention and treatment of hypertension.
    McNulty H; Strain JJ; Hughes CF; Ward M
    Mol Aspects Med; 2017 Feb; 53():2-9. PubMed ID: 27720779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene-environment interactions of selected pharmacogenes in arterial hypertension.
    Bochud M; Guessous I
    Expert Rev Clin Pharmacol; 2012 Nov; 5(6):677-86. PubMed ID: 23234325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational and Pharmacogenomic Insights on Hypertension Treatment: Rational Drug Design and Optimization Strategies.
    Loganathan L; Gopinath K; Sankaranarayanan VM; Kukreti R; Rajendran K; Lee JK; Muthusamy K
    Curr Drug Targets; 2020; 21(1):18-33. PubMed ID: 31393243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analytical validity of a genotyping assay for use with personalized antihypertensive and chronic kidney disease therapy.
    Collins KS; Pratt VM; Stansberry WM; Medeiros EB; Kannegolla K; Swart M; Skaar TC; Chapman AB; Decker BS; Moorthi RN; Eadon MT
    Pharmacogenet Genomics; 2019 Jan; 29(1):18-22. PubMed ID: 30489456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ACE Phenotyping as a Guide Toward Personalized Therapy With ACE Inhibitors.
    Danilov SM; Tovsky SI; Schwartz DE; Dull RO
    J Cardiovasc Pharmacol Ther; 2017 Jul; 22(4):374-386. PubMed ID: 28587581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Has pharmacogenetics brought us closer to 'personalized medicine' for initial drug treatment of hypertension?
    Arnett DK; Claas SA; Lynch AI
    Curr Opin Cardiol; 2009 Jul; 24(4):333-9. PubMed ID: 19509486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interpreting stimulated plasma renin and aldosterone to select physiologically individualized therapy for resistant hypertension: importance of the class of stimulating drugs.
    Huang X; Li J; Liu L; Chen G; Yi Y; Li P; Wu Y; Xu Y; Bao H; Yu L; Qin X; Zhang Y; Wang B; Li J; Fan Hou F; Huo Y; Cheng X; Spence JD
    Hypertens Res; 2019 Dec; 42(12):1971-1978. PubMed ID: 31562418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dependable approaches to hypertension management: A review.
    Elendu C; Amaechi DC; Elendu TC; Amaechi EC; Elendu ID
    Medicine (Baltimore); 2024 Jun; 103(24):e38560. PubMed ID: 38875433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From Clinical Trials to Bedside: the Use of Antihypertensives in Aged Individuals. Part 2: Approach to Treatment.
    Ernst ME; MacLaughlin EJ
    Curr Hypertens Rep; 2019 Oct; 21(11):83. PubMed ID: 31599360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Use of Precision Medicine to Manage Obstructive Sleep Apnea Treatment in Patients with Resistant Hypertension: Current Evidence and Future Directions.
    Sapiña E; Torres G; Barbé F; Sánchez-de-la-Torre M
    Curr Hypertens Rep; 2018 Jun; 20(7):60. PubMed ID: 29884918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized Therapy of Hypertension: the Past and the Future.
    Manunta P; Ferrandi M; Cusi D; Ferrari P; Staessen J; Bianchi G
    Curr Hypertens Rep; 2016 Mar; 18(3):24. PubMed ID: 26915067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple Combination Therapies Based on Olmesartan: A Personalized Therapeutic Approach to Improve Blood Pressure Control.
    Volpe M; Santolamazza C; Mastromarino V; Coluccia R; Battistoni A; Tocci G
    High Blood Press Cardiovasc Prev; 2017 Sep; 24(3):255-263. PubMed ID: 28608025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genotype-Guided Hydralazine Therapy.
    Collins KS; Raviele ALJ; Elchynski AL; Woodcock AM; Zhao Y; Cooper-DeHoff RM; Eadon MT
    Am J Nephrol; 2020; 51(10):764-776. PubMed ID: 32927458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertension Management in Stroke Prevention: Time to Consider Primary Aldosteronism.
    McCarthy J; Yang J; Clissold B; Young MJ; Fuller PJ; Phan T
    Stroke; 2021 Oct; 52(10):e626-e634. PubMed ID: 34428932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypertension: renin-angiotensin-aldosterone system alterations.
    Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
    Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.